Navigation Links
Sharp Edge Labs and SpectraGenetics Sign Agreement to Provide Better Assays for Studying G-Protein Coupled Receptors
Date:10/29/2013

PITTSBURGH, Oct. 29, 2013 /PRNewswire-iReach/ -- Sharp Edge Labs and SpectraGenetics, two Pittsburgh-based biotechnology companies, have entered into an Assay Development Agreement that will allow the companies to offer their industry leading assays for studying the detailed function of an important class of pharmaceutical targets, the G-Protein Coupled Receptors, or GPCRs.  GPCRs are the most common target of today's blockbuster drugs, including drugs for diseases ranging from hypertension and allergy to migraines, pain and cancer.  "While GPCRs are among the most-studied drug targets, we are just now learning important new aspects of how they work.  These assays provide unprecedented detail in understanding these new aspects of activity for the industry's most valuable drug targets" said Dr. Scott Sneddon, Ph.D., J.D., President and CEO of Sharp Edge Labs.  

(Photo: http://photos.prnewswire.com/prnh/20131029/MN04907)

"Working together, we can now offer a comprehensive set of tools for pharmaceutical and academic researchers including reagents and read-to-run assay kits, as well as assay services for profiling and screening compounds" added Dr. Reid Asbury, Ph.D., CEO of SpectraGenetics.  "Several large-pharma customers are already using the technology to study so-called 'ligand bias' or 'functional selectivity' of GPCRs.  By combining SpectraGenetics' catalog of over 150 GPCRs with Sharp Edge Labs' assay development expertise, we believe we can help researchers address any question in this important new field of drug research" he added.

SpectraGenetics provides research reagents to the pharma/biotech industry and academic labs.  SpectraGenetics has a large catalog of tagged genes, including a large selection of tagged GPCRs.   Sharp Edge Labs is the exclusive licensee of the Fluorogen Activating Peptide technology from CMU and provides assay products and services for pharma/biotech researchers in the areas of Receptors, Ion Channels and Transporters.  The company's web-sites are www.spectragenetics.com and www.sharpedgelabs.com.  Detailed images of the technology in use  suitable for print or web publication can be found at www.sharpedgelabs.com/media-images

Media Contact: Scott Sneddon, PhD, JD, Sharp Edge Labs, Inc., 412-475-9733, scott@sharpedgelabs.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Sharp Edge Labs, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rehrig Pacific Company Receives FDA Approval for New Reusable Sharps Container
2. Sharp Rees-Stealy Medical Centers Launches Asthmapolis Mobile Asthma Management Program
3. Safe in Commons "The Unfinished Agenda: Addressing the Challenges" Crystalizes Call for Unified Protection Against Needlestick and Sharps Injuries
4. Brain Resource Featured as Market Leader in SharpBrains New Report on The State of the Digital Brain Health Market 2012-2020
5. Daniels Sharpsmart Canada Awarded HealthPro Contract And Appoints Daniel Kennedy CEO Of Daniels Canada
6. Circassia Appoints Stewart Sharpe as Vice President Commercial Operations
7. Study Confirms Daniels Sharpsmart Helps Hospitals Reduce Carbon Footprint
8. Philips and Infraredx sign agreement for the resale of Infraredxs TVC Imaging System integrated with Philips interventional X-ray systems
9. Valeant Pharmaceuticals Announces Settlement Agreement With Anacor
10. InCube Labs Enters into an Agreement with the Engineering Research Center for Revolutionizing Metallic Biomaterials
11. Bioject Enters Into Agreement With Fondaco PTE LTD For Distribution Of Full Line Of Needle Free Injection Devices In Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology:
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):